Persistent SARS-CoV-2 Infection in a Multiple Sclerosis Patient on Ocrelizumab: A Case Report

Raghava S Ambadapoodi; Forest W Arnold; Julia H Chariker; Alex Glynn; William Lauer; Subathra Marimuthu; Eric C Rouchka; Melissa L Smith; Leslie A Wolf

doi:10.21203/rs.3.rs-2768759/v1

Persistent SARS-CoV-2 Infection in a Multiple Sclerosis Patient on Ocrelizumab: A Case Report

Res Sq [Preprint]. 2023 Apr 4:rs.3.rs-2768759. doi: 10.21203/rs.3.rs-2768759/v1.

Authors

Raghava S Ambadapoodi¹, Forest W Arnold², Julia H Chariker³, Alex Glynn², William Lauer⁴, Subathra Marimuthu², Eric C Rouchka⁴, Melissa L Smith⁴, Leslie A Wolf²

Affiliations

¹ Department of Neurology, University of Chicago Medical Center, Chicago, IL.
² Division of Infectious Diseases, School of Medicine, University of Louisville, Louisville, KY.
³ Neuroscience Training Department, University of Louisville, Louisville, KY.
⁴ Department of Biochemistry and Molecular Genetics, University of Louisville, Louisville, KY.

Abstract

A 44-year-old female patient with multiple sclerosis (MS) treated with ocrelizumab was hospitalized with SARS-CoV-2 pneumonia three times over the course of five months, eventually expiring. Viral sequencing of samples from her first and last admissions suggests a single persistent SARS-CoV-2 infection. We hypothesize that her immunocompromised state, due to MS treatment with an immunosuppressive monoclonal antibody, prevented her from achieving viral clearance.

Keywords: SARS-CoV-2; immunocompromised; long-read sequencing; multiple sclerosis; ocrelizumab; persistent infection.

Publication types

Preprint

Abstract

Publication types

Grants and funding